We are live on ! Find out more
LOAMS

Lombard Odier Asset Management (Switzerland) Portfolio holdings

AUM $2.63B
1-Year Est. Return 31.52%
This Fund
S&P 500
This Quarter Est. Return
-13.16%
1 Year Est. Return
+31.52%
3 Year Est. Return
+98.77%
5 Year Est. Return
+107.98%
10 Year Est. Return
+494.97%
AUM
$1.18B
AUM Growth
-$93.5M
Cap. Flow
+$113M
Cap. Flow %
9.6%
Top 10 Hldgs %
21.21%
Holding
341
New
184
Increased
50
Reduced
82
Closed
18

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$12.6M
2
MFC icon
Manulife Financial
MFC
+$7.56M
3
GKOS icon
Glaukos
GKOS
+$7.01M
4
AMZN icon
Amazon
AMZN
+$6.67M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$6.26M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$11.7M
2
UNH icon
UnitedHealth
UNH
+$11.3M
3
IRTC icon
iRhythm Holdings
IRTC
+$9.63M
4
HALO icon
Halozyme
HALO
+$8.33M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$7.47M

Sector Composition

Rank Sector Weight
1 Healthcare 46.65%
2 Financials 13.97%
3 Consumer Discretionary 13.94%
4 Technology 8.36%
5 Industrials 5.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GEN icon
326
Gen Digital
GEN
$17.1B
– –
-13,546
Closed -$359K
IEMG icon
327
iShares Core MSCI Emerging Markets ETF
IEMG
$158B
– –
-51,633
Closed -$2.87M
IPG
328
DELISTED
Interpublic Group of Companies
IPG
– –
-10,902
Closed -$386K
KIM icon
329
Kimco Realty
KIM
$16.2B
– –
-11,422
Closed -$282K
KKR icon
330
KKR & Co
KKR
$99.5B
– –
-16,171
Closed -$946K
LUMN icon
331
Lumen
LUMN
$6.49B
– –
-18,435
Closed -$208K
MRVI icon
332
Maravai LifeSciences
MRVI
$861M
– –
-37,000
Closed -$1.3M
RCUS icon
333
Arcus Biosciences
RCUS
$3.69B
– –
-56,484
Closed -$1.78M
STRO icon
334
Sutro Biopharma
STRO
$353M
– –
-39,102
Closed -$3.21M
VT icon
335
Vanguard Total World Stock ETF
VT
$81.4B
– –
-23,820
Closed -$2.41M
YUMC icon
336
Yum China
YUMC
$16.4B
– –
-31,690
Closed -$1.32M
GTHX
337
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-542,183
Closed -$4.12M
NXGN
338
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-83,000
Closed -$1.74M
RUBY
339
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-259,918
Closed -$1.43M
ONEM
340
DELISTED
1Life Healthcare
ONEM
– –
-40,000
Closed -$443K
CERN
341
DELISTED
Cerner Corp
CERN
– –
-18,572
Closed -$1.74M
10 11 12 13
14

Similar funds

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
CCM
Cerberus Capital Management New York $2.65B AUM 20.18% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
MAMU
Marathon Asset Management (UK) London, United Kingdom $2.61B AUM 27.14% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s Q2 2022 Portfolio in Review

As of Q2 2022, Lombard Odier Asset Management (Switzerland) held 341 positions worth $1.18B, down 7.3% from $1.27B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Lombard Odier Asset Management (Switzerland) deployed $113M of net new capital in Q2 2022, opening 184 new positions and adding to 50 existing holdings. Its largest new stake was Glaukos: 147,742 shares worth $6.71M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 57% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was AbbVie, an estimated $11.7M trimmed.

  • Lombard Odier Asset Management (Switzerland)'s largest Q2 2022 buy was Glaukos: 147,742 shares worth $6.71M.
  • Lombard Odier Asset Management (Switzerland) added most to DexCom in Q2 2022, an estimated $12.6M increase.
  • Lombard Odier Asset Management (Switzerland)'s biggest Q2 2022 reduction was AbbVie, cutting an estimated $11.7M.
  • Lombard Odier Asset Management (Switzerland) fully exited G1 Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $4.12M.
  • Lombard Odier Asset Management (Switzerland)'s ten largest holdings make up 21% of its $1.18B portfolio in Q2 2022.
  • Lombard Odier Asset Management (Switzerland) opened 184 new positions and closed 18 in Q2 2022.
  • Lombard Odier Asset Management (Switzerland)'s portfolio value fell 7.3% quarter-over-quarter to $1.18B.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2022, filed 15 Aug 2022.